Evecxia Therapeutics Reports Favorable Data From a Phase 1 Single Ascending Dose Safety/Tolerability/PK/PD Trial of EVX-301
Evecxia Therapeutics is a Duke University start-up, founded by inventors Drs. Jacob Jacobsen and Marc Caron (Cell Biology, SOM) around their serotonin synthesis amplification therapeutic technology for mental health applications.
Isolere Bio: Inside the journey of a Duke biotech start-up
From an invention in 1999, to start-up creation in 2017, to acquisition in 2023, learn of the twists and turns of Duke start-up Isolere Bio from its co-founders.
Four Points Innovation Funds Research Collaboration Between Duke University and The University of Manchester
This investment aims to accelerate research to develop a novel therapy to treat a genetic condition called Alport syndrome.
Donaldson Acquires Isolere Bio, Continuing to Build Life Sciences Business
“Isolere is thrilled to join the Donaldson family and bring our novel affinity-phase separation technology to market,” said Kelli Luginbuhl, Ph.D, co-founder and chief executive officer of Isolere.
Xilis and MD Anderson Announce Strategic Collaboration to Advance Novel Technology and Accelerate Therapeutic Development
Preclinical research agreement brings together Duke start-up Xilis' MicroOrganoSphere™ platform with MD Anderson's expertise in cancer research and therapeutic development.
Sparta Biomedical, Dr. Wiley highlighted by WXII 12 News
Professor of Chemistry Dr. Benjamin Wiley was interviewed recently by Winston-Salem TV station WXII 12 News about the synthetic cartilage his lab developed.
Duke’s Aravind Asokan, Ph.D., named Global Scholar
As a Novartis Institute for Biomedical Research (NIBR) Global Scholar, Asokan will receive up to $1 million in funding over three years, along with "drug-hunting expertise from dedicated NIBR scientific collaborators" as part of this…
Istari Oncology Announces First Patient Dosed in the Non-Muscle-Invasive Bladder Cancer (NMIBC) Substudy of the LUMINOS-103 Basket Trial Evaluating Lerapolturev Monotherapy
Istari Oncology was founded by Drs. Darell Bigner and Matthias Gromeier (Neurosurgery, SOM).
FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
Radius Health, with its eventual partner Stemline Therapeutics/Menarini Group, licensed the cancer indications for this drug in 2017 out of the lab of Dr. Donald McDonnell (Pharmacology and Cancer Biology, SOM).